OBJECTIVE: To evaluate the prognostic potential of expression of hormone receptors in malignant mammary gland tumors of dogs. Design-Cohort study. ANIMALS: 89 female dogs with malignant mammary gland tumors and 24 female dogs with benign mammary gland tumors. PROCEDURES: Female dogs with malignant (n = 89 dogs) and benign (24) mammary gland tumors were evaluated to determine the prognostic value of the expression of estrogen receptor (ER)A or the progesterone receptor (PR), as determined by use of immunohistochemical methods. RESULTS: In this study, 68 (60.2%) and 88 (77.9%) of the 113 dogs with mammary gland tumors had expression of ERA and PR, respectively. Expression of ERA and PR was detected proportionately more frequently in benign tumors (23/24 [95.8%] and 24/24 [100%], respectively) than in malignant tumors (45/89 [50.6%] and 64/89 [71.9%]). Percentage of tumors with positive results for ERA and PR was significantly higher in tumors < 5 cm in diameter; as clinical stage I, II, or III; and without metastasis to lymph nodes or distant metastasis. However, only PR expression in tumor cells was significantly associated with 1-year survival after surgical removal of the tumor. Moreover, dogs with malignant tumors expressing ERA and PR had a significantly higher survival rate, compared with the rate for dogs with malignant tumors expressing ERA but not PR. CONCLUSIONS AND CLINICAL RELEVANCE: These findings strongly suggested that expression of PR could be used as a prognostic factor for survival, especially in female dogs with malignant mammary gland tumors with ERA expression.
OBJECTIVE: To evaluate the prognostic potential of expression of hormone receptors in malignant mammary gland tumors of dogs. Design-Cohort study. ANIMALS: 89 female dogs with malignant mammary gland tumors and 24 female dogs with benign mammary gland tumors. PROCEDURES: Female dogs with malignant (n = 89 dogs) and benign (24) mammary gland tumors were evaluated to determine the prognostic value of the expression of estrogen receptor (ER)A or the progesterone receptor (PR), as determined by use of immunohistochemical methods. RESULTS: In this study, 68 (60.2%) and 88 (77.9%) of the 113 dogs with mammary gland tumors had expression of ERA and PR, respectively. Expression of ERA and PR was detected proportionately more frequently in benign tumors (23/24 [95.8%] and 24/24 [100%], respectively) than in malignant tumors (45/89 [50.6%] and 64/89 [71.9%]). Percentage of tumors with positive results for ERA and PR was significantly higher in tumors < 5 cm in diameter; as clinical stage I, II, or III; and without metastasis to lymph nodes or distant metastasis. However, only PR expression in tumor cells was significantly associated with 1-year survival after surgical removal of the tumor. Moreover, dogs with malignant tumors expressing ERA and PR had a significantly higher survival rate, compared with the rate for dogs with malignant tumors expressing ERA but not PR. CONCLUSIONS AND CLINICAL RELEVANCE: These findings strongly suggested that expression of PR could be used as a prognostic factor for survival, especially in female dogs with malignant mammary gland tumors with ERA expression.
Authors: Germana Beha; Barbara Brunetti; Pietro Asproni; Luisa Vera Muscatello; Francesca Millanta; Alessandro Poli; Giuseppe Sarli; Cinzia Benazzi Journal: BMC Vet Res Date: 2012-11-12 Impact factor: 2.741
Authors: Jérôme Abadie; Frédérique Nguyen; Delphine Loussouarn; Laura Peña; Adelina Gama; Natascha Rieder; Anton Belousov; Ingrid Bemelmans; Laëtitia Jaillardon; Catherine Ibisch; Mario Campone Journal: Breast Cancer Res Treat Date: 2017-10-23 Impact factor: 4.872
Authors: Frédérique Nguyen; Laura Peña; Catherine Ibisch; Delphine Loussouarn; Adelina Gama; Natascha Rieder; Anton Belousov; Mario Campone; Jérôme Abadie Journal: Breast Cancer Res Treat Date: 2017-10-30 Impact factor: 4.872